Standard BioTools (LAB) Competitors

10x Genomics (NASDAQ:TXG) and Standard BioTools (NASDAQ:LAB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability, risk and community ranking.

Is TXG or LAB more profitable?

10x Genomics has a net margin of -29.90% compared to Standard BioTools' net margin of -79.92%. 10x Genomics' return on equity of -25.40% beat Standard BioTools' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
10x Genomics	-29.90%	-25.40%	-19.69%
Standard BioTools	-79.92%	-27.05%	-15.52%

Does the MarketBeat Community prefer TXG or LAB?

10x Genomics received 61 more outperform votes than Standard BioTools when rated by MarketBeat users. However, 83.33% of users gave Standard BioTools an outperform vote while only 50.00% of users gave 10x Genomics an outperform vote.

Company	Underperform	Outperform
10x Genomics	Outperform Votes 66 50.00%	Underperform Votes 66 50.00%
Standard BioTools	Outperform Votes 5 83.33%	Underperform Votes 1 16.67%

Do institutionals & insiders believe in TXG or LAB?

84.7% of 10x Genomics shares are held by institutional investors. Comparatively, 53.7% of Standard BioTools shares are held by institutional investors. 9.4% of 10x Genomics shares are held by insiders. Comparatively, 23.2% of Standard BioTools shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Do analysts prefer TXG or LAB?

10x Genomics currently has a consensus price target of $15.81, indicating a potential upside of 49.27%. Standard BioTools has a consensus price target of $2.50, indicating a potential upside of 132.56%. Given Standard BioTools' stronger consensus rating and higher possible upside, analysts plainly believe Standard BioTools is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	1 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.38
Standard BioTools	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Does the media refer more to TXG or LAB?

In the previous week, 10x Genomics had 4 more articles in the media than Standard BioTools. MarketBeat recorded 6 mentions for 10x Genomics and 2 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 1.85 beat 10x Genomics' score of 0.31 indicating that Standard BioTools is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
10x Genomics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Standard BioTools	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Which has more risk & volatility, TXG or LAB?

10x Genomics has a beta of 1.99, suggesting that its share price is 99% more volatile than the S&P 500. Comparatively, Standard BioTools has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500.

Which has preferable valuation and earnings, TXG or LAB?

Standard BioTools has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$624.66M	2.09	-$182.63M	-$1.30	-8.15
Standard BioTools	$169.69M	2.41	-$74.66M	-$0.35	-3.07

Summary

Standard BioTools beats 10x Genomics on 10 of the 18 factors compared between the two stocks.